Last update 08 May 2025

CUL4B x Top II

Basic Info

Related Targets
CUL4BTop II

Related

1
Drugs associated with CUL4B x Top II
Etoposide
Target
CUL4B x Top II
Mechanism
CUL4B agonists [+1]
Active Org.
Nippon Kayaku Co., Ltd.Nippon Kayaku Co., Ltd. [+8]
Originator Org.
Corden Pharma Latina SpA
Active Indication
Bladder Cancer [+21]
Inactive Indication
acute leukemia [+28]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date10 Nov 1983
1,547
Clinical Trials associated with CUL4B x Top II
NCT05403723
/ SuspendedPhase 1IIT
A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination with Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer
100 Clinical Results associated with CUL4B x Top II
Login to view more data
100 Translational Medicine associated with CUL4B x Top II
Login to view more data
0 Patents (Medical) associated with CUL4B x Top II
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free